

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (canceled)
2. (currently amended) The pharmaceutical composition of claim ~~[[4]]~~ 5, further comprising:
a carrier molecule that can be internalized by a living cell wherein the carrier molecule forms a conjugate with one or more Se(0) particles.
3. (canceled)
4. (canceled)
5. (previously presented) A pharmaceutical composition comprising:
elemental selenium (Se(0)) particles having a diameter of 0.4 to 1 nanometer; and
a pharmaceutically acceptable delivering medium.
6. (currently amended) The pharmaceutical composition of claim ~~[[4]]~~ 5, wherein the elemental selenium (Se(0)) particles can form a Se(0) colloid in a dispersion medium.
7. (currently amended) A pharmaceutical composition comprising:
elemental selenium (Se(0)) particles having a diameter of 0.4 to ~~5 nanometers~~ 1 nanometer;
a target cell-specific carrier molecule that can be internalized by a living cell wherein the carrier molecule forms a conjugate with one or more Se(0) particles; and
a pharmaceutically acceptable delivering medium.

8. (original) The composition of claim 2, wherein the carrier molecule is selected from the group consisting of proteins, glycoproteins and lipoproteins.

9. (original) The composition of claim 2, wherein the carrier molecule is selected from the group consisting of albumin, high density lipoprotein, low density lipoprotein and very low density lipoprotein.

10. (currently amended) A pharmaceutical composition comprising:
elemental selenium (Se(0)) particles having a diameter of 0.4 to ~~5 nanometers~~ 1 nanometer;
a target cell-specific carrier molecule that can be internalized by a living target cell wherein the carrier molecule is albumin and forms a conjugate with one or more Se(0) particles; and
a pharmaceutically acceptable delivering medium.

11. (currently amended) A pharmaceutical composition comprising:
elemental selenium (Se(0)) particles having a diameter of 0.4 to ~~5 nanometers~~ 1 nanometer;
a target cell-specific carrier molecule that can be internalized by a living target cell selected from the group consisting of a cancer cell, an immune cell responsible for an autoimmune disorder, an alloreactive lymphocyte responsible for graft-versus-host disease or a rejection reaction, a parasite and a parasitized blood cell, wherein the carrier molecule forms a conjugate with one or more Se(0) particles; and
a pharmaceutically acceptable delivering medium.

12. (previously presented) The composition of claim 11, wherein the living target cell is a cancer cell.

13-25. (canceled)

26. (original) A method for generating Se(0) comprising the steps of:
providing a photosensitizing selone dye;
exposing the dye to light of a suitable wavelength in the presence of molecular oxygen; and
purifying Se(0).

27. (original) The method of claim 26, wherein the photosensitizing selone dye is selected from the group consisting of a selenomero cyanine dye and a selenooxonol dye.

28. (original) The method of claim 27, wherein the selenomero cyanine dye is selected from the group consisting of MC54, MC55, MC56 and MC57.

29. (original) The method of claim 26, wherein Se(0) is colloidal Se(0).

30. (original) The method of claim 26, wherein the light of suitable wavelength is generated by light-emitting diodes (LED).

31-51. (canceled)

52. (currently amended) A method for treating a human or nonhuman subject having cancer ~~causing a cancer cell to die~~ comprising the step of:
administering a composition that comprises a pharmaceutically effective amount of Se(0) particles to the human or non-human subject.

~~treating the cancer cell, or a human or nonhuman subject having the cancer cell, with a composition that comprises Se(0) particles in an amount sufficient to kill the cancer cell.~~

53. (previously presented) The method of claim 52, wherein the Se(0) particles have a diameter of 0.4 to 5 nanometers.

54. (previously presented) The method of claim 52, wherein the Se(0) particles can form a Se(0) colloid in a dispersion medium.

55. (previously presented) The method of claim 52, wherein the composition further comprises a carrier molecule that can be internalized by a cancer cell to form a conjugate with one or more Se(0) particles.

56. (previously presented) The method of claim 55, wherein the carrier molecule is albumin.

57. (previously presented) A method for sensitizing a cell to a cytotoxic agent wherein the cell is resistant to the cytotoxic agent due to the presence of intracellular glutathione, the method comprising the step of:

treating the cell, or a human or nonhuman subject having the cell, with a composition that comprises Se(0) particles wherein the cell becomes susceptible to the killing by an otherwise ineffective amount of the cytotoxic agent.

58-66. (canceled)